<DOC>
	<DOCNO>NCT02103374</DOCNO>
	<brief_summary>Design study nebulization COPD respond adequately clinically relevant question : intervention administer nebulized bronchodilator home likely make profit , compare standard optimize treatment define recommendation SPLF , patient severe COPD ( stage III , FEV 30 % 50 % theoretical value ) severe ( stage IV , less 30 % theoretical value FEV ) ? The concept profit context base criterion dyspnea , quality life , use health system ( exacerbation , hospitalization , prescription antibiotic steroid ... ) .</brief_summary>
	<brief_title>Evaluation Benefit Nebulized Bronchodilators Home Severe Chronic Obstructive Pulmonary Disease Very Severe Steady State</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Adult COPD Patients stage 3 et 4 Has submit exacerbation 3 month precede preinclusion visit Weaned tobacco least 6 month vaccinate pneumococcal Have include pulmonary rehabilitation program 6 month precede screen visit inclusion Patient preincluded show exacerbation since preinclusion visit Patient nebulizer treat nebulized bronchodilator home last 6 month Patient indication oxygen expect coming year Progressive malignant disease know Patient noninvasive ventilation ( NIV ) less 6 month NIV provide follow year Patient known colonize Pseudomonas aeruginosa , A. xylosoxidans , Burkholderia cepacia Stenotrophomonas maltophilia Patients severe cardiovascular disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>wean tobacco</keyword>
	<keyword>Has submit exacerbation past 3 month</keyword>
</DOC>